| 1. Saito M, Usuku K, Nose H, Sabouri AH, Arimura K, Izumo S, Osame
M, Ohara Y. Virus-host reactions and its implication in the development of
HTLV-I-Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP). Current
Topics in Neuroimmunology. 41-46, 2006.
2. Taylor GP, Goon P, Furukawa Y, Green H, Barfield A, Mosley A, Nose H,
Babiker A, Rudge P, Usuku K, Osame M, Bangham CR, Weber JN. Zidovudine plus
lamivudine in Human T-Lymphotropic Virus type-I-associated myelopathy: a
randomised trial.Retrovirology. 3:63-71, 2006.
3. Nose H, Saito M, Usuku K, Sabouri AH, Matsuzaki T, Kubota R, Eiraku N,
Furukawa Y, Izumo S, Arimura K, Osame M. Clinical symptoms and the odds of human
T-cell lymphotropic virus type 1-associated myelopathy/ tropical spastic
paraparesis (HAM/TSP) in healthy virus carriers: application of best-fit
logistic regression equation based on host genotype, age, and provirus load. J
Neurovirol. 123:171-177, 2006.
4. Saito M, Nose H, Usuku K, Sabouri AH, Matsuzaki T, Izumo S, Arimura K,
Osame M. Flow cytometry evaluation of the T-cell receptor Vbeta repertoire among
human T-cell lymphotropic virus type-1 (HTLV-1) infected individuals: effect of
interferon alpha therapy in HTLV-1-associated myelopathy/tropical spastic
paraparesis (HAM/TSP). J Neurol Sci. 246:37-343, 2006.
5. Nobuhara Y, Usuku K, Saito M, Izumo S, Arimura K, Bangham CR, Osame M.
Genetic variability in the extracellular matrix protein as a determinant of risk
for developing HTLV-I-associated neurological disease. Immunogenetics.
57:944-952, 2006.
6.
高田彰，菊池健：クリクラナビ 基本的臨床能力学習ガイド（熊本大学医学部臨床実習入門コースワーキンググループ編集委員会編集）６情報管理，36-41頁，金原出版，東京，2006
7. Nakanishi J, Wada Y, Matsumoto K, Azuma M, Kikuchi K, Ueda S:
Overexpression of B 7-H1 (PD-L1) significantly associates with tumor grade and
postoperative prognosi s in human urothelial cancers. Cancer Immunol Immunother,
2006 Dec 22; [Epub ahead of print] doi: 10.1007/s00262-006 -0266-z, 2007
8. Wada Y, Kikuchi K, Takahashi W, Honda J, Nakanishi J, Matsumoto K,
Kuwahara T, Kai N, Kikukawa H, Ueda S: Docetaxel, low-dose estramustine, and
doxifluridine in hormone-refractory metastatic prostate cancer. Cancer
Chemotherapy and Pharmacology, . 2007 Mar 21; [Epub ahead of print]
doi:10.1007/s00280-007-0445-4, 2007
|
